Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Sponsored by Revolution Medicines, Inc.
About this study
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
This is a Phase 1/2, multicenter open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of escalating doses of RMC-6236 in adult patients with advanced solid tumors harboring specific RAS mutations, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose \[RP2D\] within investigated patient population groups. RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms (HRAS, NRAS, and KRAS).
Where this study is enrolling
- Call 877-632-6789
The University of Texas MD Anderson Cancer Center
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
- ✓Treatment naive or have received prior standard therapy appropriate for tumor type and stage
- ✓Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- ✓Adequate organ function
Exclusion criteria
- ✕Primary central nervous system (CNS) tumors
- ✕Active, untreated brain metastases
- ✕Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- ✕History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
- ✕Other inclusion/exclusion criteria may apply.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.